NLRP3 and keloid: Moreover, the use of NLRP3 inhibitor MCC950 reduced the expression of IL-1β (Ogawa, 2017; Perera et al., 2018), and inhibiting the activation of IL-1 β in inflammatory body may be a method to inhibit keloid.